tetano
Editor, Senior Moderator
Nat Commun
. 2022 Jan 25;13(1):446.
doi: 10.1038/s41467-021-27797-1.
Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome
Carlo Cervia[SUP] 1 [/SUP], Yves Zurbuchen[SUP] 1 [/SUP], Patrick Taeschler[SUP] 1 [/SUP], Tala Ballouz[SUP] 2 [/SUP], Dominik Menges[SUP] 2 [/SUP], Sara Hasler[SUP] 1 [/SUP], Sarah Adamo[SUP] 1 [/SUP], Miro E Raeber[SUP] 1 [/SUP], Esther Bächli[SUP] 3 [/SUP], Alain Rudiger[SUP] 4 [/SUP], Melina Stüssi-Helbling[SUP] 5 [/SUP], Lars C Huber[SUP] 5 [/SUP], Jakob Nilsson[SUP] 1 [/SUP], Ulrike Held[SUP] 2 [/SUP], Milo A Puhan[SUP] 2 [/SUP], Onur Boyman[SUP] 6 7 [/SUP]
Affiliations
Abstract
Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals with COVID-19. Our results highlight the benefit of measuring Igs for the early identification of patients at high risk for PACS, which facilitates the study of targeted treatment and pathomechanisms of PACS.
. 2022 Jan 25;13(1):446.
doi: 10.1038/s41467-021-27797-1.
Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome
Carlo Cervia[SUP] 1 [/SUP], Yves Zurbuchen[SUP] 1 [/SUP], Patrick Taeschler[SUP] 1 [/SUP], Tala Ballouz[SUP] 2 [/SUP], Dominik Menges[SUP] 2 [/SUP], Sara Hasler[SUP] 1 [/SUP], Sarah Adamo[SUP] 1 [/SUP], Miro E Raeber[SUP] 1 [/SUP], Esther Bächli[SUP] 3 [/SUP], Alain Rudiger[SUP] 4 [/SUP], Melina Stüssi-Helbling[SUP] 5 [/SUP], Lars C Huber[SUP] 5 [/SUP], Jakob Nilsson[SUP] 1 [/SUP], Ulrike Held[SUP] 2 [/SUP], Milo A Puhan[SUP] 2 [/SUP], Onur Boyman[SUP] 6 7 [/SUP]
Affiliations
- PMID: 35078982
- DOI: 10.1038/s41467-021-27797-1
Abstract
Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals with COVID-19. Our results highlight the benefit of measuring Igs for the early identification of patients at high risk for PACS, which facilitates the study of targeted treatment and pathomechanisms of PACS.